INTRODUCTION
Translocation of the insulin-regulated glucose transporter GLUT4 from an intracellular pool to the plasma membrane is an essential step in the stimulation of glucose transport by insulin [1] . The mechanisms involved in this regulation remain incompletely understood. The involvement of phosphoinositide 3-kinase is well documented [1] [2] [3] [4] but other signalling systems might also be involved [5] . Evidence suggesting an involvement of protein kinase C (PKC) includes the ability of insulin to induce the translocation of both conventional and atypical PKC isoforms to the plasma mebrane [6] [7] [8] . Moreover, the insulininduced stimulation of GLUT4 translocation can be partly mimicked by activators of PKC [9] [10] [11] [12] and prevented by nonspecific protein kinase inhibitors [13, 14] . Using adipocytes permeabilized with streptolysin-O (SLO), we have recently demonstrated [15] that insulin-induced increases in PKC activity [16] and GLUT4 translocation are both blocked by internalization of the PKC (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) pseudosubstrate peptide, a highly specific inhibitor of PKC. Moreover, an atypical PKC isoform is required for the stimulation of glucose uptake by insulin in 3T3-L1 adipocytes [17] . These observations indicate that the PKC-dependent phosphorylation of plasma membrane substrate(s) might be involved in insulin-dependent GLUT4 vesicle translocation. The present study examines whether the Abbreviations used : ICM, intracellular membrane fraction ; PKA ; cAMP-dependent protein kinase ; PKC, protein kinase C ; PLM, phospholemman ; PM, plasma membrane fraction ; SLO, streptolysin-O ; SNARE, soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptor. 1 Deceased. 2 To whom correspondence should be addressed (e-mail ivar.walaas!basalmed.uio.no).
streptolysin-O-permeabilized adipocytes, the peptide decreased the effects of insulin on both the phosphorylation of phospholemman and the recruitment of GLUT4 to the plasma membrane. Similarly, the internalization of phospholemman antibodies, which also decreased the protein kinase C-mediated phosphorylation of the synthetic phospholemman peptide in itro, decreased the effect of insulin on GLUT4 translocation in the adipocytes.
The results suggest that phosphorylation of the intracellular domain of phospholemman might be involved in modulating the insulin-induced translocation of GLUT4 to the plasma membrane.
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inhibition of the insulin-stimulated phosphorylation of phospholemman (PLM), a plasma membrane PKC substrate, leads to the modulation of insulin-dependent GLUT4 translocation. PLM, originally observed in skeletal muscle sarcolemma as a substrate for an endogenous insulin-and GTP-sensitive protein kinase [18] , is a 72-residue transmembrane plasmalemma protein with an intracellular, positively charged C-terminal phosphorylation domain (G&)TFRSSIRRLSTRRR(#) [19] . Studies in itro indicate that PKC phosphorylates both Ser-63 and Ser-68, and cAMP-dependent protein kinase (PKA) phosphorylates Ser-68, whereas studies on intact muscle indicate that insulin or active phorbol esters increase the $#P labelling of both Ser-63 and Ser-68 in situ [20, 21] . The function of PLM, which seems to be enriched in striated muscle [19] and the gene for which is localized to human chromosome 19q13.1 [22] , is not well defined. Because the expression of PLM in Xenopus oocytes induces anion-permeable conductances [23] , and the reconstitution of PLM in lipid bilayers forms taurine-selective channels [24] , the transmembrane PLM domain seems to behave like a channel.
Here we demonstrate that the internalization into permeabilized adipocytes of either a synthetic peptide encompassing the intracellular PLM(58-72) phosphorylation domain but with alanine residues replacing Ser-63 and Ser-68, or of antibodies directed towards this PLM domain, decreases the insulin effects on both PLM phosphorylation and GLUT4 translocation in the cells. Our results indicate that phosphorylation of the intracellular domain of PLM might modulate insulin-induced trafficking of GLUT4 vesicles. 
MATERIALS AND METHODS

Materials
Antibody preparation
Polyclonal antibody against whole PLM was raised by isolating rat muscle PLM [20] , immunizing rabbits as described [25] and purifying the antiserum by the method of Olmsted [26] . Antiserum against the PLM(58-72) peptide was prepared (MedProbe AS, Oslo, Norway) by conjugating the synthetic peptide to keyhole limpet haemocyanin and immunizing rabbits with it. Both
Figure 1 Immunoblot of PLM in rat adipocyte membranes
A 100 000 g membrane pellet from rat adipocytes, together with prestained molecular mass markers (Rainbow ; Amersham) included in the outer lanes, was subjected to SDS/PAGE on gels containing 15 % (w/v) polyacrylamide ; proteins were electrotransferred to PVDF membranes. After blocking, the membrane was incubated with preimmune rabbit IgG (lane A) or antipeptide PLM(58-72) antibody (lane B) (both at 1 : 100 dilution) for 1 h, followed by washing. The immune complex was detected by incubation with 125 I-protein A and autoradiography. The 15 kDa immunoreactive PLM band is indicated.
antibodies recognized essentially only one band of approx. molecular mass 15 kDa when tested by immunoblotting on a total membrane preparation (prepared by centrifugation at 100 000 g ; see below) from rat adipocytes ( Figure 1 ) and skeletal muscle (results not shown). Immunoblotting was performed by separating proteins by SDS\PAGE, transferring the sample to PVDF membranes [27] and incubating the membranes with primary antibodies followed by "#&I-Protein A as described (see [15] ).
Cell preparation
Adipocytes were isolated from epididymal fat pads from 8-12 rats by the method of Rodbell [28] . After dissection, the fat pads were minced and incubated in ' extracellular ' buffer [129 mM NaCl\5 mM KCl\1.2 mM MgCl # \1.3 mM CaCl # \ 1.2 mM KH # PO % \20 mM Hepes (pH 7.4)] containing 2 mM sodium pyruvate and 2 % (w\v) BSA. Collagenase was added and the incubation was continued for 90 min at 37 mC. The cells were filtered through a nylon screen and washed four times by flotation and resuspension in extracellular buffer. In permeabilization experiments, the cells were subsequently washed once and then resuspended in ' intracellular ' buffer [20 mM Hepes (pH 7.4)\120 mM KCl\4 mM NaCl\10 mM MgCl
Determination of protein kinase activity
Determination of PKC activity in itro with the PLM(58-72) peptide as substrate was done as reported previously [21] . In brief, 250 µM PLM(58-72) peptide was incubated at 30 mC in 50 mM Hepes, pH 7.4, with 1.25 mM CaCl # , 1 mM EGTA, 10 mM MgCl # , 200 µM [γ-$#P]ATP, 50 µg\ml phosphatidylserine and 2.5 nM PKC β II . PKA activity was determined as described [21] . Reactions were terminated after 5 min by the addition of 7 % (w\v, final concn.) trichloroacetic acid ; aliquots were spotted on P81 phosphocellulose paper squares (Whatman). After washing, radioactivity was determined by Cerenkov counting.
Determination of PKC activity in situ in SLO-permeabilized adipocytes was done essentially as described [15, 29] . Washed cell suspension in ' intracellular ' buffer was incubated with SLO (2 i.u.\ml) at 37 mC in plastic vials containing (final concns.) 25 mM Hepes, pH 7.4, 600 µM [γ-$#P]ATP and 10 mM MgCl # , with 250 µM PLM(58-72) as substrate, with or without 5-40 µM Ala-PLM(58-72) and in the absence or presence of 100 nM insulin. Reactions were terminated after 5 min as described above. Samples were centrifuged at 10 000 g for 8 min, aliquots of the supernatants were spotted on P81 phosphocellulose paper and radioactivity was determined as described.
Analysis of PLM phosphorylation in adipocytes
For the determination of PLM phosphorylation in itro in adipocyte membranes, untreated adipocytes were homogenized in 250 mM sucrose\25 mM NaF\1 mM EDTA\10 µg\ml leupeptin\25 mM Hepes (pH 7.4). Membranes were prepared by centrifugation at 100 000 g for 5 h, then suspended in 50 mM Hepes (pH 7.4)\1 mM EDTA\2.5 mM EGTA\10 µg\ml leupeptin\0.5 % CHAPS and phosphorylated as described [20] . After SDS\PAGE, the $#P-labelled PLM band was identified by autoradiography.
For the determination of PLM phosphorylation in situ in permeabilized adipocytes, cells were incubated with SLO and 600 µM [γ-$#P]ATP, in the absence or presence of 100 nM insulin and with or without 40 µM Ala-PLM(58-72), as described above.
Reactions were terminated by the addition of 250 mM sucrose\25 mM NaF\10 µg\ml leupeptin\25 mM Hepes (pH 7.4) containing 0.1 M EDTA ; membranes were prepared by centrifugation at 100 000 g for 5 h. Membrane phosphoproteins were solubilized in SDS sample buffer, identified by SDS\PAGE and autoradiography, and quantified by Cerenkov counting of the excised gel bands.
For the determination of PLM phosphorylation in situ in intact adipocytes, the cells were preincubated with [$#P]P i (0.5 mCi\ml) for 2 h. Cell aliquots were then incubated with insulin (final concn. 100 nM) or PMA, a specific activator of PKC (final concn. 500 nM) for 10 min. After homogenization and centrifugation as described above, the membrane fractions were subjected to SDS\PAGE and the $#P-labelled PLM band was detected by autoradiography. Thermolytic digestion of PLM and the two-dimensional separation of phosphopeptides on silicacontaining thin-layer plates were done as previously described [20] .
Immunoprecipitation of PLM
Immunoprecipitation of PLM from $#P-labelled fat cells was done by solubilizing the 100 000 g membrane pellet in 1 % (w\v) SDS, followed by the addition of a 5-fold excess of Triton X-100. After the addition of anti-peptide antiserum (final dilution 1 : 100) or purified anti-PLM antibody (0.46 µg) in the presence of 1 % (w\v) BSA, the antigen-antibody complex was isolated as described [30] , dissolved in SDS sample buffer and subjected to SDS\PAGE. $#P-labelled PLM was demonstrated by autoradiography.
Translocation of GLUT4
Washed cell suspensions were suspended in ' intracellular ' buffer containing SLO (2 i.u.\ml), 200 nM adenosine and 5 mM ATP. Incubation was done at 37 mC for 10 min in plastic vials in the absence or presence of 100 nM insulin, and with the addition of various concentrations of the Ala-PLM(58-72) peptide or PLM antibodies as reported in the text. Control samples were incubated in preimmune serum or rabbit IgG (Sigma), none of which had any effect on the distribution of GLUT4 in the absence or presence of insulin (results not shown). The cells were floated and washed in homogenization buffer [250 mM sucrose\10 mM NaF\10 mM sodium pyrophosphate\10 µg\ml leupeptin\ 25 mM Tris\HCl buffer (pH 7.4)]. The plasma membrane (PM) and total intracellular membrane (ICM) fractions were prepared as reported previously [15] by differential centrifugation by a modification of the method of Karnieli et al. [31] . PM was isolated by centrifugation at 10 600 g for 20 min ; ICM was isolated by centrifugation of the supernatant at 100 000 g for 5 h. The pelleted fractions were suspended in SDS sample buffer, boiled for 2 min and subjected to SDS\PAGE. Quantitative immunoblotting analysis of GLUT4 was done as described [15] .
RESULTS
Effects of Ala-PLM(58-72) peptide on PLM phosphorylation in vitro
When the phosphorylation of PLM(58-72) catalysed by PKC β II was examined in itro [21] , addition of the Ala-PLM(58-72) peptide in the low micromolar range gave a marked but partial inhibition of enzyme activity (Figure 2 ). In contrast, Ala-PLM(58-72) had no inhibitory effect on the PKA-catalysed phosphorylation of PLM(58-72). A kinetic analysis with doublereciprocal plots indicated a non-competitive type of PKC in- hibition (results not shown). These results suggest that PKC is subject to a mixed type of inhibition by Ala-PLM(58-72), similar to the effects found with other Ala-substituted PKC substrate peptides, which might be caused by multiple binding sites with distinct affinities [32] .
Phosphorylation of PLM in adipocytes
Incubation of intact adipocytes in the presence of [$#P]P i , followed by the isolation of the membrane fraction and analysis by SDS\PAGE and autoradiography, showed a broad $#P-labelled band with an molecular mass of approx. 15 kDa ( Figure 3A ). This electrophoretic mobility, which is similar to that of PLM from skeletal muscle [19, 20] , was shared by a $#P-labelled 15 kDa band present in a 100 000 g adipocyte membrane fraction that had been phosphorylated in itro in the presence of [γ-$#P]ATP and purified PKC or PKA (results not shown). Moreover, the phosphorylation of this band seemed to be increased when the cells had been incubated in the presence of 500 nM PMA ( Figure 3A) . The 15 kDa $#P-labelled protein was also recognized
Figure 3 Effects of PMA and insulin on PLM phosphorylation in intact adipocytes
Adipocytes were prelabelled with 0.5 mCi/ml [ 32 P]P i for 2 h followed by incubation for 10 min in the absence (lanes 1 and 3) or presence of either 500 nM PMA (lane 2) or 100 nM insulin (lane 4). After isolation of the membranes by 100 000 g centrifugation, the membrane pellets from samples shown in (A) (lanes 1 and 2) were subjected to protein separation by SDS/PAGE. The membrane pellets from samples shown in (B) (lanes 3 and 4) were solubilized in 1 % (w/v) SDS ; 32 P-labelled PLM was immunoprecipitated with polyclonal antibodies raised against the PLM(58-72) peptide as described in the Materials and methods section. The 32 P-labelled 15 kDa PLM bands (arrowed) were detected by autoradiography. Results are taken from one representative experiment, which was repeated twice with similar results.
Figure 4 Effect of PMA on 32 P-labelling of Ser-63 and Ser-68 in adipocyte PLM
(A) Peptide map of PLM(58-72) phosphorylated by PKC in vitro (see Figure 2 ). (B, C) Peptide maps of the 15 kDa bands phosphorylated in intact adipocytes in the absence (B) or presence (C) of 500 nM PMA. The 32 P-labelled 15 kDa bands (see Figure 3) were excised from the gel and subjected to phosphopeptide mapping with thermolysin as described in the text. The spots labelled a and b are peptides comprising phosphoserine-63 and phosphoserine-68 respectively, the phosphorylation sites in PLM.
by antibodies raised against the C-terminal PLM(58-72) peptide ( Figure 3B ) and by polyclonal antibodies raised against skeletal muscle PLM (results not shown) ; the incorporation of $#P into this immunoreactive band was markedly increased in adipocytes that had been incubated with 100 nM insulin ( Figure 3B ).
The phosphorylation sites in the 15 kDa protein labelled by PKC in intact adipocytes were characterized further. Extensive two-dimensional thermolytic peptide mapping of the $#P-labelled 15 kDa bands isolated from adipocytes incubated in the absence or presence of 500 nM PMA showed two major $#P-labelled peptides, designated a and b (Figures 4B and 4C ). These peptides co-migrated with thermolytic peptides derived from the PLM(58-72) peptide phosphorylated with PKC in itro ( Figure  4A ), and also with thermolytic peptides derived from skeletal muscle PLM phosphorylated in the presence of insulin or PMA (results not shown). The latter have been identified as PLM residues Ser-63 and Ser-68 respectively [21] . A third, apparently unrelated, $#P-labelled thermolytic peptide (designated c), although present in control samples, was absent from the PLM(58-72) peptide and was not investigated further.
Taken together, these results indicate that PLM is expressed in fat cells, where it is subject to the same enzymic and hormonal regulation of phosphorylation as in skeletal muscle [20, 21] . 
Effects of Ala-PLM(58-72) peptide on insulin-stimulated PLM phosphorylation in SLO-permeabilized adipocytes
The efficacy of insulin-induced protein phosphorylation in SLOpermeabilized adipocytes was first examined with exogenous PLM(58-72) added as substrate [15] . This phosphorylation of PLM(58-72), which seems to be catalysed by PKC [15] , reached 218 % of control activity in the presence of 100 nM insulin ( Figure 5A ). This insulin effect was inhibited in a dose-dependent manner by the addition of Ala-PLM(58-72) to the permeabilization medium, with an apparent IC &! of 6-8 µM and a maximal effect of 75 % inhibition at 20 µM peptide ( Figure  5B ).
In some experiments (results not shown), we examined the phosphorylation of native PLM in situ ; it was also found to be sensitive to internalization of Ala-PLM(58-72). In these experiments, SLO-permeabilized adipocytes were incubated with 300 µM [γ-$#P]ATP for 5 min and PLM phosphorylation was analysed by SDS\PAGE of membrane proteins as described Insulin-induced GLUT4 translocation and phospholemman
Figure 6 Effect of Ala-PLM(58-72) on insulin-dependent translocation of GLUT4 in SLO-permeabilized adipocytes
(A) Inhibition of insulin-induced increase in GLUT4 in PM and decrease in the ICM fraction by Ala-PLM(58-72) (final concn. 20 µM). Adipocytes were incubated for 10 min with SLO in the absence or presence of insulin (Ins) (100 nM final concn.) and Ala-PLM(58-72) (final concn. 20 µM). The GLUT4 transporters in the PM and ICM were isolated and identified by immunoblotting and quantified as described in the Materials and methods section. Results are presented as relative values (control l 1), and are meanspS.E.M. (n l 4 to 6). The significance of insulin-and Ala-PLM-peptide-induced effects on GLUT4 translocation, compared with control values, was examined by ANOVA and t test. *P 0.05 ; **P 0.01. (B) Concentration-dependent inhibition of insulin-dependent translocation of GLUT4 to PM by Ala-PLM(58-72). Adipocytes were incubated as described above in the absence or presence of insulin (100 nM final concn.) and Ala-PLM(58-72). Results are meanspS.E.M. for four to six experiments and are plotted as percentages of insulin-induced GLUT4 translocation observed in the absence of Ala-PLM(58-72). The significance of the Ala-PLM-peptide effects on insulin-induced GLUT4 translocation was examined by ANOVA and t test. *P 0.05 ; **P 0.01.
above. A considerable increase in $#P-labelling of the 15 kDa PLM band was found in the insulin-treated samples ; this effect was markedly decreased when 20 µM Ala-PLM(58-72) was present during incubation (results not shown).
Effects of Ala-PLM(58-72) peptide on insulin-induced GLUT4 translocation in SLO-permeabilized adipocytes
To examine the effect on GLUT4 trafficking, the relative concentrations of GLUT4 in fractions enriched in PM and ICM from the SLO-permeabilized adipocytes were quantified by immunoblotting. We observed recently [15] that incubation of SLO- permeabilized adipocytes with insulin gives an approx. 4-fold increase in immunoreactive GLUT4 levels in PM, with a simultaneous decrease of GLUT4 in the ICM fraction ( Figure 6A ). These observations are similar to previous results obtained in intact adipocytes and SLO-permeabilized 3T3-L1 cells [33] . In this study, the addition of Ala-PLM(58-72) to the permeabilization medium inhibited the insulin effect in a dosedependent manner, with an apparent IC &! of 6-8 µM and a maximal effect of 70 % inhibition at 20 µM peptide ( Figure 6B ).
Effects of PLM antibodies on insulin-induced GLUT4 translocation in SLO-permeabilized adipocytes
Both anti-[PLM(58-72)] antiserum and antibodies raised against the muscle PLM protein inhibited the phosphorylation in itro of the (58-72)PLM peptide catalysed by PKC, but not that by PKA ( Figure 7A , and results not shown). Internalization of these antibodies into SLO-treated adipocytes gave an approx. 65 % inhibition of insulin-dependent GLUT4 translocation to PM in comparison with incubation with preimmune serum or rabbit IgG ( Figure 7B ). The preimmune sera or IgG preparations had no effect by themselves (results not shown). The antibodies thus mimicked the inhibition obtained by the Ala-PLM(58-72) peptide under similar experimental conditions.
DISCUSSION
PLM is one of the major insulin-regulated PKC substrates in skeletal muscle [20] . Here we demonstrate that this protein is also present in fat cells and that it might be involved in the modulation of insulin-induced GLUT4 translocation. The experimental approach that we used to examine this question employed the introduction of distinct peptide and antibody inhibitors of PLM phosphorylation into permeabilized adipocytes, followed by an analysis of insulin responses in these cells.
We have previously shown that the C-terminal PLM(58-72) peptide is a good substrate for PKC, with insulin-induced phosphorylation in skeletal muscle in situ occurring at Ser-63 and Ser-68 [21] . The present results show that a synthetic PLM(58-72) peptide, where the two phosphorylation sites were replaced by alanine residues, can serve as an inhibitor of PLM phosphorylation. Employing the cognate PLM(58-72) peptide as substrate, this Ala-PLM(58-72) peptide behaved as a noncompetitive inhibitor of PKC activity in itro, inducing an incomplete inhibition with an apparent IC &! of 6-8 µM. When this Ala-PLM(58-72) peptide was introduced into SLOpermeabilized adipocytes, the insulin-induced increases of phosphorylation of both internalized exogenous PLM(58-72) and of the native PLM protein present in the SLO-permeabilized adipocytes were decreased. Moreover, our results indicate that this peptide also antagonizes effects of insulin on GLUT4 translocation in the SLO-permeabilized adipocytes, again with an apparent IC &! comparable to that found when PKC was assayed in itro.
To complement the studies with the PLM peptide analogue, which presumably interferes with PLM functions, PLM antibodies were generated and tested as insulin antagonists. Polyclonal antibodies raised either against the PLM(58-72) peptide or the whole PLM protein each behaved as monospecific reagents, recognizing only the PLM band on immunoblots of adipocyte membrane proteins. Employing these antibodies during phosphorylation assays in itro showed that they specifically decreased the phosphorylation of PLM(58-72) catalysed by PKC but not that by PKA. This suggests that these antibodies specifically interfered with interactions between PKC and the intracellular PLM domain. When these antibodies were added to the permeabilized adipocytes, they mimicked the ability of the Ala-PLM(58-72) peptide to inhibit the effects of insulin on GLUT4 translocation.
Therefore two distinct inhibitors of PLM phosphorylation both decreased the effects of insulin on GLUT4 translocation. The mechanisms involved in GLUT4 translocation remain incompletely understood [1, 5, 34] . GLUT4 vesicle trafficking shares many characteristics with the soluble N-ethylmaleimidesensitive fusion protein attachment protein receptor (SNARE) model for the exocytosis of synaptic vesicles in nerve terminals [35] [36] [37] . Insulin has been reported to translocate v-SNAREs of the synaptobrevin family, present in GLUT4 vesicles, to the plasma membrane ; syntaxin 4, a member of the syntaxin t-SNARE family, has been identified in a complex with GLUT4, the N-ethylmaleimide-sensitive fusion protein and α-soluble Nethylmaleimide-sensitive fusion (' NSF ') protein attachment protein (' α-SNAP ') in adipocyte plasma membranes [38] [39] [40] [41] .
A role for PKC in neurotransmitter release (see [42, 43] ), possibly modulating SNARE interactions [44] , is well documented. Similarly, strong support for a role of PKC in insulin-dependent GLUT4 translocation was recently obtained [15, 17] . PKC substrate(s) might therefore be involved in exocytotic reactions. The present results indicate that the inhibition of insulin-stimulated, PKC-mediated phosphorylation of PLM leads to a significant inhibition of insulin-dependent translocation of GLUT4 to PM. These results are consistent with the hypothesis that a causal relationship between insulinstimulated phosphorylation of the C-terminal intracellular PLM domain and insulin-induced GLUT4 translocation might exist.
